The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS). Celgene was originally a unit of Celanese. In 1986, Celanese completed the corporate spin-off of Celgene following the merger of Celanese with American Hoechst.
In August 2000, Celgene acquired Signal Pharmaceuticals, Inc., a privately held company that developed pharmaceuticals to regulate disease-related genes. Signal Pharmaceuticals was rebranded as Celgene Research San Diego.
In December 2002, Celgene acquired Anthrogenesis, a privately held New Jersey-based biotherapeutics company and cord blood banking business, which is developing technology for the recovery of stem cells from placental tissues following the completion of full-term successful pregnancies. Anthrogenesis was rebranded as Celgene Cellular Therapeutics.
In 2006, Celgene certified McKesson Specialty, a specialty pharmacy, as one of a group of pharmacies contracted to launch lenalidomide (Revlimid). As a specialty drug, lenalidomide is only available through the a distribution network consisting of specialty pharmacies contracted by the company.
In January 2019, the company announced it would be acquired by Bristol-Myers Squibb for $74 billion ($95 billion including debt), a deal that would become the largest pharmaceutical company acquisition ever.
Celebrating the 76th anniversary of Syria's Independence Day (April 17, 1946 - April 17, 2022)
Celebrating the 185th birthday of John Pierpont Morgan, the founder of J.P. Bank. Morgan (April 17, 1837 - April 17, 2022)
According to Wikipedia